Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom
Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by snake venoms. In this study, we examined the ac...
Main Authors: | Pamella G. Gutierres, Diego R. Pereira, Nataly L. Vieira, Lilian F. Arantes, Nelson J. Silva, Kristian A. Torres-Bonilla, Stephen Hyslop, Karen Morais-Zani, Rosa M. B. Nogueira, Edward G. Rowan, Rafael S. Floriano |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.812295/full |
Similar Items
-
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting <em>Naja</em> Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)
by: Mátyás A. Bittenbinder, et al.
Published: (2018-12-01) -
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation
by: Matthew Lewin, et al.
Published: (2016-08-01) -
Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms
by: José María Gutiérrez, et al.
Published: (2020-02-01) -
Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation
by: Yiding Wang, et al.
Published: (2018-02-01) -
PLA<sub>2</sub> Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper <i>Vipera berus nikolskii</i>
by: Oleksandr Zinenko, et al.
Published: (2020-05-01)